Welcome Guest!  Login | Register | Help
Home News Screener Maps Groups Portfolio Insider Futures Forex Collaborate Store Elite
Settings
SRPT [NASD]
Sarepta Therapeutics, Inc.
Index- P/E- EPS (ttm)-2.82 Insider Own0.40% Shs Outstand40.68M Perf Week-7.08%
Market Cap827.02M Forward P/E- EPS next Y-2.95 Insider Trans3.83% Shs Float37.71M Perf Month-32.62%
Income-98.20M PEG- EPS next Q-0.75 Inst Own69.90% Short Float29.15% Perf Quarter-45.22%
Sales15.80M P/S52.34 EPS this Y35.60% Inst Trans5.50% Short Ratio7.85 Perf Half Y-19.17%
Book/sh6.05 P/B3.36 EPS next Y4.20% ROA-37.20% Target Price37.23 Perf Year-42.10%
Cash/sh5.54 P/C3.67 EPS next 5Y15.97% ROE-48.40% 52W Range12.12 - 55.61 Perf YTD-0.20%
Dividend- P/FCF- EPS past 5Y-9.80% ROI-36.30% 52W High-58.46% Beta0.38
Dividend %- Quick Ratio6.60 Sales past 5Y-7.80% Gross Margin- 52W Low90.59% ATR1.40
Employees146 Current Ratio6.60 Sales Q/Q35.60% Oper. Margin- RSI (14)43.74 Volatility5.29% 6.67%
OptionableYes Debt/Eq0.01 EPS Q/Q43.20% Profit Margin- Rel Volume2.09 Prev Close20.33
ShortableYes LT Debt/Eq0.01 EarningsAug 04 Payout- Avg Volume1.40M Price23.10
Recom2.40 SMA20-0.96% SMA50-19.91% SMA200-16.30% Volume2,439,248 Change13.63%
29-Jul-14Upgrade WBB Securities Speculative Buy → Buy $25
22-Apr-14Reiterated Needham Buy $36 → $52
22-Apr-14Reiterated Deutsche Bank Hold $17 → $35
04-Mar-14Reiterated Canaccord Genuity Hold $25 → $27
21-Jan-14Upgrade Needham Hold → Buy $36
26-Nov-13Upgrade WBB Securities Sell → Speculative Buy $9 → $19
13-Nov-13Downgrade Needham Buy → Hold
13-Nov-13Downgrade Deutsche Bank Buy → Hold $71 → $17
12-Nov-13Reiterated FBR Capital Mkt Perform $48 → $20
30-Oct-13Initiated FBR Capital Mkt Perform $48
06-Sep-13Initiated Stifel Buy $51
22-Apr-13Initiated Needham Buy $57
04-Apr-13Initiated Robert W. Baird Outperform $63
03-Apr-13Initiated Robert W. Baird Outperform $63
08-Mar-13Reiterated Burrill Institutional Research Mkt Outperform $54 → $39
26-Nov-12Initiated Burrill Institutional Research Mkt Outperform $54
12-Sep-12Downgrade WBB Securities Hold → Sell $8 → $9
09-Aug-12Initiated WBB Securities Hold $8
09-Aug-12Downgrade WBB Securities Speculative Buy → Hold
30-Jul-14 11:33AM  Sarepta Up 12% As FDA Is 'Actively Engaged' On Drug Application Benzinga +13.63%
11:22AM  Here's Why Aegerion and Sarepta Trade Higher Wednesday at TheStreet
29-Jul-14 03:16PM  [$$] Sarepta CEO Sheds Some Sway Over Management at The Wall Street Journal
09:06AM  Sarepta Therapeutics upgraded by WBB Securities Briefing.com
28-Jul-14 08:00AM  Stop Squabbling, Mom Tells Troubled Biotech: 'Just Get My Kid the Drug' at BusinessWeek
08:00AM  Mom Tells Troubled Biotech to Stop Squabbling: 'Just Get My Kid the Drug' at BusinessWeek
25-Jul-14 08:18AM  [$$] Chief Scientist Out at Sarepta Therapeutics at The Wall Street Journal
07:48AM  [$$] Chief Scientist Out at Sarepta Therapeutics at The Wall Street Journal
06:58AM  [$$] Chief Scientist Out at Sarepta Therapeutics at The Wall Street Journal
12:02AM  [$$] Chief Scientist Out at Sarepta Therapeutics at The Wall Street Journal
24-Jul-14 11:03PM  [$$] Chief Scientist Out at Sarepta Therapeutics at The Wall Street Journal
09:08PM  [$$] Chief Scientist Out at Sarepta Therapeutics at The Wall Street Journal
07:25PM  [$$] Chief Scientist Is Out at Biotech at The Wall Street Journal
09:37AM  Sarepta fired CSO not involved in eteplirsen, The Street reports theflyonthewall.com
09:21AM  The Story Behind Sarepta's Firing of its Top Scientist at TheStreet
06:52AM  Sarepta terminates Chief Scientific Officer Arthur Krieg at theflyonthewall.com
06:31AM  SAREPTA THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers EDGAR Online
23-Jul-14 04:38PM  [video] PTC Therapeutics CFO: Positive News on Translarna Just the Start at TheStreet
09:01AM  Edelman's Perceptive Advisors Buying Amicus Therapeutics Ahead Of Phase III Data Release at Seeking Alpha
19-Jul-14 09:12AM  Roundtable: 3 Stocks Janet Yellen Is Dead Wrong About at Motley Fool
17-Jul-14 06:10PM  Your first trade for Friday at CNBC
05:59PM  [video] Fast Money Final Trade: GOOGL, MSFT & more at CNBC
08:12AM  The Zacks Analyst Blog Highlights: AbbVie, Shire, Gilead Sciences, Sarepta Therapeutics and Celgene Zacks
12-Jul-14 06:01PM  3 Stocks Crushed by the Market This Week at Motley Fool
11-Jul-14 04:33PM  3 Reasons Not to Worry About Sarepta Therapeutics Inc. at Motley Fool
04:00PM  Sarepta Plunges on Eteplirsen Study Results Zacks
09:49AM  Today's Dead Cat Bounce Stock Is Sarepta Therapeutics (SRPT) at TheStreet
08:50AM  Today's Top Biotech Stocks to Watch: Johnson & Johnson and Sarepta Therapeutics at Motley Fool
07:03AM  Sarepta Therapeutics Slumps: SRPT Tanks 12.9% in Session Zacks
10-Jul-14 05:45PM  [video] Stock Pops & Drops: COH, SRPT, CRAY, LB at CNBC -12.94%
04:26PM  Should Sarepta's Shares Be Tumbling? at Motley Fool
03:24PM  Deutsche Bank Questions Long-Term Efficacy Of Sarepta's Eteplirsen Following Trial News Benzinga
02:10PM  Why Sarepta Therapeutics Inc. Stock Collapsed at Motley Fool
01:39PM  Investors Remain Confident in Sarepta After Shares Fall 20 Percent StockTwits
01:28PM  Sarepta price target lowered to $34 from $52 at Roth Capital theflyonthewall.com
12:38PM  Sarepta potential for near-term approval lower after update, says Piper Jaffray theflyonthewall.com
11:52AM  Janney Capital reiterates Sell rating on Sarepta at theflyonthewall.com
11:50AM  Sarepta story correction issued by Wall Street Journal at theflyonthewall.com
11:38AM  Down 17%: Is Sarepta a Bad News Buy? at Motley Fool
10:54AM  Sarepta shares defended at Needham at theflyonthewall.com
10:51AM  Why Sarepta Therapeutics (SRPT) Stock Is Plunging Today at TheStreet
10:09AM  Sarepta shares fall on muscular dystrophy drug data at CNBC
08:47AM  Sarepta Releases New Data, Facing A Sea Change At Regulators at Forbes
08:47AM  Sarepta Data Disappoints Wall Street As Expert Sees A Sea Change At FDA at Forbes
08:47AM  Sarepta Data Disappoints As Expert Sees A Sea Change At FDA at Forbes
08:32AM  Sarepta says on track to initiate several new studies of eteplirsen at theflyonthewall.com
08:31AM  Latest Sarepta Study Update Shows Greater Decline in Walking Ability at TheStreet
08:31AM  [video] Sarepta to file for approval of Eteplirsen at CNBC
08:30AM  Sarepta Therapeutics Reports Long-Term Outcomes Through 144 Weeks from Phase IIb Study of Eteplirsen in Duchenne Muscular Dystrophy Business Wire
08-Jul-14 01:06PM  [video] Rough day for biotech at CNBC -7.29%
07:06AM  Sarepta Therapeutics (SRPT) Enters Oversold Territory Zacks
07-Jul-14 02:49PM  Sarepta's Monday Selloff on New (Old) Worries Addressed at TheStreet -7.36%
27-Jun-14 06:22AM  SAREPTA THERAPEUTICS, INC. Files SEC form 8-K/A, Submission of Matters to a Vote of Security Holders EDGAR Online
06:22AM  SAREPTA THERAPEUTICS, INC. Files SEC form 8-K/A, Submission of Matters to a Vote of Security Holders
24-Jun-14 08:10AM  Short Interest is Piling Up in Sarepta Therapeutics (SRPT) Stock, Time to Panic? Zacks
08:10AM  Short Interest is Piling Up in Sarepta Therapeutics (SRPT) Stock, Time to Panic?
18-Jun-14 04:30PM  Sarepta Therapeutics to Present Company Overview at the JMP Securities Healthcare Conference on June 24 Business Wire
04:30PM  Sarepta Therapeutics to Present Company Overview at the JMP Securities Healthcare Conference on June 24
09-Jun-14 12:59PM  SHAREHOLDER ALERT: The Law Firm of Levi & Korsinsky, LLP Launches an Investigation into Sarepta Therapeutics Inc. Regarding Possible Breaches of Fiduciary Duty PR Newswire
12:59PM  SHAREHOLDER ALERT: The Law Firm of Levi & Korsinsky, LLP Launches an Investigation into Sarepta Therapeutics Inc. Regarding Possible Breaches of Fiduciary Duty
07-Jun-14 06:33PM  Why Wall Street is Betting Heavily Against Sarepta Therapeutics at Motley Fool
06:33PM  Why Wall Street is Betting Heavily Against Sarepta Therapeutics
06-Jun-14 05:11PM  SAREPTA THERAPEUTICS, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders EDGAR Online
05:11PM  SAREPTA THERAPEUTICS, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders
04-Jun-14 06:02PM  What You Need to Know About PTC Therapeutics' Promising DMD Drug at Motley Fool
06:02PM  What You Need to Know About PTC Therapeutics' Promising DMD Drug
03-Jun-14 09:21AM  Tuesdays Top Biotech Stories: Vanda Pharmaceuticals, Prosensa, and Clovis Oncology at Motley Fool
09:21AM  Tuesdays Top Biotech Stories: Vanda Pharmaceuticals, Prosensa, and Clovis Oncology
07:39AM  Prosensa to Seek U.S. Approval for DMD Drug at TheStreet
07:39AM  Prosensa to Seek U.S. Approval for DMD Drug
02-Jun-14 09:34AM  Sarepta Therapeutics Opens New Global Headquarters in Cambridge, Mass. Business Wire
09:34AM  Sarepta Therapeutics Opens New Global Headquarters in Cambridge, Mass.
31-May-14 11:56PM  Surprising MS Drug Approval: Time to Buy? at Motley Fool
11:56PM  Surprising MS Drug Approval: Time to Buy?
28-May-14 04:32PM  SAREPTA THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and E EDGAR Online
04:32PM  SAREPTA THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and E
27-May-14 01:12PM  3 Stocks That Soared Stupendously Last Week at Motley Fool
23-May-14 03:45PM  Sarepta to Acquire Manufacturing Facility Zacks
01:28PM  Isis Pharmaceuticals: 'The Best Pipeline in Biotech,' Potential Takeover Target at Barrons.com
12:37PM  PTC Muscular Dystrophy Drug Wins EU Panel Vote at Investor's Business Daily
12:04PM  PTC Muscular Dystrophy Drug Wins EU Panel Vote at Investor's Business Daily
10:25AM  [video] Ataluren drives PTC Therapeutics at CNBC
08:46AM  PTC Therapeutics Gets Warm Hug From Europe for DMD Drug; Prosensa Rises in Sympathy at TheStreet
07:12AM  [$$] Sarepta Looks Like a First-Mover at Barrons.com
22-May-14 11:36AM  Sarepta gearing for potential 2015 launch of eteplirsen, says Piper Jaffray at theflyonthewall.com
08:56AM  Today's Top Health Care Stocks to Watch: Celgene Corporation and Sarepta Therapeutics, Inc. at Motley Fool
08:32AM  Sarepta announces acquisition of Massachusetts manufacturing facillity at theflyonthewall.com
08:30AM  Sarepta Therapeutics Announces Agreement for Acquisition of Manufacturing Facility in Massachusetts Business Wire
07:07AM  Sarepta initiated with a Buy at Roth Capital at theflyonthewall.com
20-May-14 05:02PM  Sarepta Therapeutics' (SRPT) CEO Presents at UBS Global Healthcare Conference (Transcript) at Seeking Alpha
16-May-14 01:04PM  SAREPTA THERAPEUTICS, INC. Financials EDGAR Online Financials
08:30AM  Sarepta Therapeutics to Present Company Overview at the UBS Global Healthcare Conference on May 20 Business Wire
14-May-14 06:17PM  Sarepta Therapeutics' (SRPT) CEO Chris Garabedian Hosts Sarepta DMD Development Program Update (Transcript) at Seeking Alpha
13-May-14 04:24PM  Sarepta Therapeutics' (SRPT) CEO Christopher Garabedian on Bank of America Merrill Lynch Health Care Conference (Transcript) at Seeking Alpha
11:00AM  Sarepta Therapeutics Inc Conference Call to discuss DMD Development Program Update scheduled for 11:00 am ET today CCBN
11:00AM  Electro Scientific Industries, Inc. Earnings Call scheduled for 11:00 am ET today CCBN
07:34AM  Sarepta Therapeutics Inc Conference Call to discuss DMD Development Program Update scheduled for 11:00 am ET today CCBN
12-May-14 12:24PM  Busy Days Ahead for Sarepta Therapeutics at Motley Fool
10-May-14 06:02PM  Sarepta Therapeutics's (SRPT) CEO Chris Garabedian Presents at Deutsche Bank Healthcare Conference (Transcript) at Seeking Alpha
09-May-14 03:03PM  Sarepta to hold a conference call at theflyonthewall.com
Sarepta Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery and development of RNA-based therapeutics for the treatment of rare and infectious diseases. Its lead product candidate is Eteplirsen, an antisense PMO-based therapeutic in clinical development for the treatment of individuals with Duchenne muscular dystrophy. The company is also involved in developing treatments that are in clinical development include AVI-7288 for the treatment of Marburg virus and AVI-7100 for the treatment of influenza. In addition, it focuses on developing preclinical research product candidates for the treatment of other neuromuscular, infectious, and rare diseases. Sarepta Therapeutics, Inc. was founded in 1980 and is headquartered in Cambridge, Massachusetts.